Occult macular dystrophy | |
---|---|
Specialty | Ophthalmology |
Occult macular dystrophy (OMD) is a rare inherited degradation of the retina, characterized by progressive loss of function in the most sensitive part of the central retina (macula), the location of the highest concentration of light-sensitive cells (photoreceptors) but presenting no visible abnormality. "Occult" refers to the degradation in the fundus being difficult to discern. [1] The disorder is called "dystrophy" instead of "degradation" to distinguish its genetic origin from other causes, such as age. OMD was first reported by Y. Miyake et al. in 1989. [2] [3]
Symptoms entail a loss of visual acuity in both eyes, including darkened vision, ring scotoma (ring of blindness close to the center of vision), color blindness, and difficulty with bright lights. The scotoma may cause text slightly away from the center of vision to disappear; the appearance would not be black (in early stages) but of the same color as the nearby background. Many lines of an Amsler grid would be faded or invisible to the patient. The area of invisibility on the Amsler grid spreads with time. Symptoms do not include headaches or eye pain. The loss of acuity tends to be symmetric between the eyes.
OMD that is caused by mutations of the retinitis pigmentosa 1-like 1 (RP1L1) [4] gene (OMIM 608581) is called Miyake's disease. [1] [5] While the mutation is dominant, OMD may manifest more strongly and earlier in children than in the parent (anticipation). [2] [6] However, cases have presented with no mutation to RP1L1. [6] [7] One study suggests that OMD arises because of two mutations arising simultaneously, one in RP1L1 and another in ABCA4. [8]
OMD is generally believed to be autosomal dominant, meaning that if you get the abnormal gene from only one parent, you can get the disease. However, this does not always seem to be the case. [7]
OMD differentiates from Stargardt macular dystrophy in which gene is mutated (RP1L1 instead of ABCA4), the process of OMD isn't a buildup of toxic lipofuscin, [9] and Stargardt is regressive. [10] [11]
The connection between these mutations and OMD is unclear, but cone density is significantly lower in patients with OMD compared to the general population. Use of adaptive optics to obtain high-resolution retinal images reveal abnormal changes in patients with OMD, including thinning of the foveal thickness and the outer nuclear layer and disruption of the IS/OS line and COST line. [6]
OMD returns negative results for a funduscopic inspection, fluorescein angiogram, and full-field electroretinogram (ERG), [4] for both rod and cone components. The key to diagnosing this disorder is the multifocal ERG (mfERG), providing a single procedure for diagnosis. [6] Onset is known to range from age 6 to 81, with about half of onsets occurring after age 65. [1]
A visual field test can differentiate between whether the reduced visual acuity is centered on the optic nerve or the fundus.
Once a neurological problem has, therefore, been ruled out, the disorder's reduced visual acuity without visible fundus abnormalities may be misdiagnosed as optic neuritis, dominant optic atrophy, amblyopia, or nonorganic visual disorder. [12]
The combination of weak amplitudes in the mfERG with no visible fundus abnormalities then rules out other explanations. For example, OMD presents negative for a full-field ERG while retinitis pigmentosa presents abnormal. [13] [14]
Since the abnormality is not in the eye lens, the disease is not correctable with eyeglasses. Vision becomes dimmer over the course of years as the macula loses function. Eventually the patient may become legally blind. The peripheral vision field is preserved. In other words, OMD does not cause total blindness, due to the concentration of the degradation at the cone-rich (color-sensitive) region of the retina. No treatment is known to slow the progression. The speed of progression varies by case — even between donor and recipient of the mutation [2] — and can last for 10 to 30 years. [5]
Because of the rarity of OMD, no clinical trials are in the pipeline as of January 2019. [15] However, mutations in RP1L1 might play a role in retinitis pigmentosa (RP), [16] [17] raising hope for a spillover effect for OMD patients should an RP1L1-related treatment be developed for RP. Given the possible relation between ABCA4 and OMD, [8] progress with Stargardt disease via gene therapy might have a spillover effect for OMD patients as well.
Adeno-associated viral (AAV) vectors have been particularly successful in gene therapy of eyes and muscles. [18] Unfortunately, their size is limited--too limited to hold the RP1L1 gene. [19] Therefore, a non-viral approach would need to be developed for gene therapy to treat OMD. Since RP1 has the same size problem, a gene therapy for RP could have a spillover effect for OMD.
A stem-cell approach might entail taking stem cells from the patient, editing the mutation with CRISR, and inserting the stem cells in the eye. However, as of 2014, researchers did not yet know if retinal stem cell surgery would work. [20]
Prevalence is unknown, [21] but seems to be elevated in Asian populations, given that most OMD studies are of Japanese and Korean subjects. [22] Given that Stargardt's, the most common macular dystrophy, has a prevalence of 1 in 10,000 in the US, [10] [11] the prevalence of OMD is likely well below 1 in 100,000.
Retinitis pigmentosa (RP) is a genetic disorder of the eyes that causes loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.
Electroretinography measures the electrical responses of various cell types in the retina, including the photoreceptors, inner retinal cells, and the ganglion cells. Electrodes are placed on the surface of the cornea or on the skin beneath the eye to measure retinal responses. Retinal pigment epithelium (RPE) responses are measured with an EOG test with skin-contact electrodes placed near the canthi. During a recording, the patient's eyes are exposed to standardized stimuli and the resulting signal is displayed showing the time course of the signal's amplitude (voltage). Signals are very small, and typically are measured in microvolts or nanovolts. The ERG is composed of electrical potentials contributed by different cell types within the retina, and the stimulus conditions can elicit stronger response from certain components.
Leber's hereditary optic neuropathy (LHON) is a mitochondrially inherited degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; it predominantly affects young adult males. LHON is transmitted only through the mother, as it is primarily due to mutations in the mitochondrial genome, and only the egg contributes mitochondria to the embryo. Men cannot pass on the disease to their offspring. LHON is usually due to one of three pathogenic mitochondrial DNA (mtDNA) point mutations. These mutations are at nucleotide positions 11778 G to A, 3460 G to A and 14484 T to C, respectively in the ND4, ND1 and ND6 subunit genes of complex I of the oxidative phosphorylation chain in mitochondria.
A cone dystrophy is an inherited ocular disorder characterized by the loss of cone cells, the photoreceptors responsible for both central and color vision.
Choroideremia is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life. Progression continues throughout the individual's life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.
Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.
Oguchi disease is an autosomal recessive form of congenital stationary night blindness associated with fundus discoloration and abnormally slow dark adaptation.
ATP-binding cassette, sub-family A (ABC1), member 4, also known as ABCA4 or ABCR, is a protein which in humans is encoded by the ABCA4 gene.
Peripherin-2 is a protein, that in humans is encoded by the PRPH2 gene. Peripherin-2 is found in the rod and cone cells of the retina of the eye. Defects in this protein result in one form of retinitis pigmentosa, an incurable blindness.
Bestrophin-1 (Best1) is a protein that, in humans, is encoded by the BEST1 gene.
Retinaldehyde-binding protein 1 (RLBP1) also known as cellular retinaldehyde-binding protein (CRALBP) is a 36-kD water-soluble protein that in humans is encoded by the RLBP1 gene.
11-cis retinol dehydrogenase is an enzyme that in humans is encoded by the RDH5 gene.
Crumbs homolog 1 is a protein that in humans is encoded by the CRB1 gene.
Fascin-2 is a protein that in humans is encoded by the FSCN2 gene.
Cytochrome P450 4V2 is a protein that in humans is encoded by the CYP4V2 gene.
The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cures for the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness.
Retinal degeneration is a retinopathy which consists in the deterioration of the retina caused by the progressive death of its cells. There are several reasons for retinal degeneration, including artery or vein occlusion, diabetic retinopathy, R.L.F./R.O.P., or disease. These may present in many different ways such as impaired vision, night blindness, retinal detachment, light sensitivity, tunnel vision, and loss of peripheral vision to total loss of vision. Of the retinal degenerative diseases retinitis pigmentosa (RP) is a very important example.
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness.
Goldmann–Favre syndrome is a rare genetic disorder characterized by early-onset nyctalopia, decreased visual acuity, and abnormal findings of the fundus. It is a type of progressive vitreotapetoretinal degeneration.
Progressive bifocal chorioretinal atrophy, also known for its abbreviations PBCRA or CRAPB, is a rare, slowly progressive, autosomal dominant syndrome characterized by relatively large-sized atrophic hole-shaped lesions in the macular and nasal retina, myopia, low visual acuity, and nystagmus. It has been described in one family from Scotland and two families from France. The condition is caused by point mutations in a region in the long arm of chromosome 6 (6q16.2) that has been found responsible for the pathogenesis of other macular dystrophies.
{{cite web}}
: CS1 maint: multiple names: authors list (link)